Stay updated with breaking news from Rush alzheimer. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Groundbreaking treatments for Alzheimer's disease that work by removing a toxic protein called beta amyloid from the brain may benefit whites more than Black Americans, whose disease may be driven by other factors, leading Alzheimer's experts told Reuters. The two drugs – Leqembi, from partner biotech firms Eisai and Biogen, and an experimental treatment developed by Eli Lilly, donanemab - are the first to offer real hope of slowing the fatal disease for the 6.5 million Americans living with Alzheimer's. Although older Black Americans have twice the rate of dementia as whites, they were screened out of clinical trials of these drugs at a higher rate, according to interviews with 10 researchers as well as 4 Eisai and Lilly executives. ....
Insight: Promising new Alzheimer's drugs may benefit whites more than Blacks reuters.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from reuters.com Daily Mail and Mail on Sunday newspapers.
Alzheimer's drugs Leqembi donanemab may benefit Black people less nbcnews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from nbcnews.com Daily Mail and Mail on Sunday newspapers.
Researchers revealed that older Black Americans, who have twice the rate of dementia compared to whites were excluded from clinical trials of these drugs ....
Promising new Alzheimer's drugs may be less effective for Black patients today.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from today.com Daily Mail and Mail on Sunday newspapers.